Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice.
We have found previously that the tumor cell lines, Renca (a renal cancer) and MC38 (a colon tumor) which had been injected subcutaneously in mice, could be successfully treated with a combination therapy of an oligodeoxynucleotide (CpG1826) (injected intratumorally) and anti-CD137 antibody (injecte...
Guardado en:
Autores principales: | Jennifer A Westwood, Titaina C U Potdevin Hunnam, Hollie J Pegram, Rodney J Hicks, Phillip K Darcy, Michael H Kershaw |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd5b3730ab394de5b229a7bcf7cbde95 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
por: Stefan Nierkens, et al.
Publicado: (2009) -
Low biological fluctuation of mitochondrial CpG and non-CpG methylation at the single-molecule level
por: Chloe Goldsmith, et al.
Publicado: (2021) -
CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen W, et al.
Publicado: (2021) -
Centromere evolution and CpG methylation during vertebrate speciation
por: Kazuki Ichikawa, et al.
Publicado: (2017) -
Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
por: Hanagata N
Publicado: (2012)